<< Вернуться к списку статей журнала

Том 7 №2 2005 год - Нефрология и диализ

Перитонеальный диализ: отдаленные результаты лечения, факторы, их определяющие, и клиническая патофизиология метода (Обзор литературы)

Андрусев А.М.

Аннотация: Лечение хронической почечной недостаточности (ХПН) стоит в ряду наиболее актуальных задач современного здравоохранения. Решение этой проблемы непосредственно связано с развитием заместительной почечной терапии, одним из видов которой является постоянный амбулаторный перитонеальный диализ (ПАПД).

Для цитирования: Андрусев А.М. Перитонеальный диализ: отдаленные результаты лечения, факторы, их определяющие, и клиническая патофизиология метода (Обзор литературы). Нефрология и диализ. 2005. 7(2):110-129. doi:

Весь текст

Ключевые слова: перитонеальный диализ, отдаленные результаты, выживаемость больных, выживаемость метода, патофизиология

Список литературы:

1. Бикбов Б.Т., Кирхман В.В., Ушакова А.И. и соавт. Предикторы летального исхода у больных на гемодиализе. Нефрология и диализ 2004; 6 (2): 154-163.
2. Волгина Г.В., Перепеченых Ю.В., Бикбов Б.Т. Кальцификация клапанов сердца у больных с терминальной хронической почечной недостаточностью. Нефрология и диализ 2001; 3 (1): 46-52.
3. Волгина Г.В., Перепеченых Ю.В., Бикбов Б.Т. и соавт. Факторы риска кардиоваскулярных заболеваний у больных с хронической почечной недостаточностью. Нефрология и диализ 2000; 2 (4): 252-259.
4. Гуревич А.К., Константинов Ю.В., Васильева Г.В. и соавт. Перитонеальный диализ в схемах и таблицах. СПб., 2003: 55.
5. Гуревич К.Я., Константинов Ю.В., Шумилкин В.Р. и соавт. Перитонеальный диализ (пособие для врачей). СПб., 2003: 98.
6. Ермоленко В.М. Хроническая почечная недостаточность. В кн.: Нефрология: руководство. Под ред. И.Е. Тареевой. М.: Медицина, 2000: 596-657.
7. Ермоленко В.М., Иващенко М.А. Уремия и эритропоэтин. М., 2000: 105.
8. Земченков А.Ю., Константинов Ю.В., Шумилкин В.Р. и соавт. Шестилетний опыт программы перитонеального диализа в Санкт-Петербурге. Нефрология и диализ 2001; 3 (2): 164-165.
9. Милованова Л.Ю., Николаев А.Ю., Козлова Т.А. и соавт. Прогностическое значение ранней коррекции анемии у больных с хронической почечной недостаточностью. Нефрология и диализ 2004; 6 (1): 54-57.
10. Перова Н.В. Атерогенные нарушения метаболизма липидов. Нефрология и диализ 2001; 3 (3): 325-327.
11. Райхельсон К.Л. Влияние нутриционного статуса и гастродуоденальной патологии на прогноз и течение терминальной стадии хронической почечной недостаточности при применении активных методов лечения (гемодиализ, перитонеальный диализ, трансплантация): Автореф.. канд. мед. наук. СПб., 1999: 24.
12. Саенко Ю.В., Шутов А.М. Роль оксидативного стресса в патологии сердечно-сосудистой системы у больных с заболеваниями почек (Сообщение I. Патофизиология оксидативного стресса). Нефрология и диализ 2004; 6 (1): 47-53.
13. Саенко Ю.В., Шутов А.М. Роль оксидативного стресса в патологии сердечно-сосудистой системы у больных с заболеваниями почек (Сообщение II. Клинические аспекты оксидативного стресса). Нефрология и диализ, 2004; 6 (2): 138-144.
14. Томилина Н.А., Волгина Г.В., Бикбов Б.Т., Ким И.Г. Проблема сердечно-сосудистых заболеваний при хронической почечной недостаточности. Нефрология и диализ, 2003; 5 (1): 15-24.
15. Шутов Е.В. Постоянный амбулаторный перитонеальный диализ в лечении терминальной уремии: Автореф.. д-ра мед. наук. М., 2000: 41.
16. Abraham G., Gupta A. Peritoneal dialysis in developing countries. In: Gokal R., Khanna R., Krediet R.T., Nolph K.D. (eds). Textbook of Peritoneal Dialysis (ed 2) 2000: 829-847. Dordrecht/Boston/London, Kluwer Academic Publishers.
17. Agrawal A., Nolph K.D. Management of high peritoneal transporters. Perit Dial Int 2000; 23 (Suppl. 2): 160-165.
18. Anglani F., Forino M., Del Prete D. et al. Molecular biology of the peritoneal membrane: in between morphology and function. In: Ronco C. (eds). Contributions to nephrology 2001; 131. Advanced glycation end products in nephrology: 61-73. Karger.
19. Apostolou T., Gokal R. Quality of life after peritoneal dialysis. In: Gokal R., Khanna R., Krediet R.T., Nolph K.D. (eds). Textbook of Peritoneal Dialyasis (ed 2) 2000: 709-735. Dordrecht/Boston/London, Kluwer Academic Publishers.
20. Araki Y., Hataya H., Tanaka Y., Fukuzawa R. et al. Long-term peritoneal dialysis is a risk factor of sclerosing encapsulating peritonitis in children. Perit Dial Int 2000; 20 (Suppl. 3): 445-451.
21. Ash S.R., Daugirdas J.T. Peritoneal dialysis access. In: Daugirdas J.T., Ing T.S. (eds). Handbook of Dialyasis (ed 2) 1994: 274-309, Boston/Little/Brown.
22. Avram M.M., Mittman N., Bonomini L. et al. Markers for survival in dialysis: a seven-year prospective study. Am J Kidney Dis 1995; 26: 209-219.
23. Balaskas E.V., Ikonopoulos D., Sioulis A. et al. Survival and complications of 225 catheters used in continuous ambulatory peritoneal dialysis: One-center experience in Northern Greece. Perit Dial Int 1999; 19 (Suppl. 2): 167-171.
24. Bargman J.M. Non-infectious complications of peritoneal dialysis. In: Gokal R., Khanna R., Krediet R.T., Nolph K.D. (eds). Textbook of Peritoneal Dialysis (ed 2) 2000: 609-646. Dordrecht/Boston/London, Kluwer Academic Publishers.
25. Bargman J.M., Throrpe K.E., Churchill D.N. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: A reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12: 2158-2162.
26. Beddhu S., Bruns F.J., Saul M. et al. A simple comorbidity scale predicts clinical outcomes and cost in dialysis patients. Am J Med 2000; 108: 609-613.
27. Berlanga J.R., Marron B., Reyero A. et al. Peritoneal dialysis retardation of progression of advanced renal failure. Perit Dial Int 2002; 22: 239-242.
28. Bernardini J. Peritoneal dialysis catheter complications. Perit Dial Int 1996; 16 (Suppl. 1): 468-471.
29. Bertoli M., Bonfante L., Gambaro G. et al. Peritoneal dialysis in diabetic patients. In: Ronco C. (eds). Contributions to nephrology 2001; 131. Advanced glycation end products in nephrology: 51-60. Karger.
30. Bertoli S.V., Ciurlino D.C., Maccario M.M. et al. Peritoneal dialysis in elderly patients. Perit Dial Int 2004; 24 (Suppl. 2): 31 (Abstr.).
31. Blake P.G. What is the problem with high transporters? Perit Dial Int 1997; 17: 317-320.
32. Bleyer A.J., Burkart J.M., Russell G.B., Adams P.L. Dialysis modality and delayed graft function after cadaveric renal transplantation. J Am Soc Nephrol 1999; 10: 154-159.
33. Block G.A., Hulbert-Shearon T.E., Levin N.W., Port F.K. Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
34. Bloembergen W.E., Port K.F., Mayger A., Wolfe R.A. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis. J Am Soc Nephrol 1995; 6: 177-183.
35. Boeschoten E.W. Continuous ambulatory peritoneal dialysis. In: Gokal R., Khanna R., Krediet R.T., Nolph K.D. (eds). Textbook of Peritoneal Dialyasis (ed 2) 2000: 387-417. Dordrecht/Boston/London, Kluwer Academic Publishers.
36. Bostom A.G., Lathrop L. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52: 10-20.
37. Breborowicz A., Oreopoulus D.G. Evidence for the presence of chronic inflammation during peritoneal dialysis: Therapeutic implications. Perit Dial Int 1997; 17 (Suppl. 2): 37-41.
38. Breborowicz A., Oreopoulus D.G. Physiological approaches to increase biocompatibility of peritoneal dialysis. Perit Dial Int 1995; 15 (Suppl. 7): 76-86.
39. Burkart J.M. Adequacy of peritoneal dialysis. In: Gokal R., Khanna R., Krediet R.T., Nolph K.D. (eds). Textbook of Peritoneal Dialyasis (ed 2) 2000: 465-497. Dordrecht/Boston/London, Kluwer Academic Publishers.
40. Cancarini G.C., Sandrini M., Vizzardi V. et al. Long-term peritoneal dialysis outcome in a single center. Perit Dial Int 2000; 20 (Suppl. 2): 121-126.
41. Catalán M.P., Subirá D., Reyero A. et al. Regulation of apoptosis by lethal cytokines in human mesothelial cells. Kidney Int 2003; 64: 321-330.
42. Cendoroglo M., Jaber B.L., Balakrishnan V.S. et al. Neutrophil apoptosis and dysfunction in uremia. J Am Soc Nephrol 1999; 10: 93-100.
43. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chron Dis 1987; 40: 373-383.
44. Cheigh J.C., Kim H. Hypertension in continuous ambulatory peritoneal dialysis patients: what do we know and what can we do about it? Perit Dial Int 1999; 19 (Suppl. 2): 138-143.
45. Chen Y.M., Yang A.H., Lin J.K. et al. Absence of modulating effects of cytokines on antioxidant enzymes in peritoneal mesothelial cells. Perit Dial Int 1997; 17: 455-466.
46. Cheng S.C., Chu T.S., Huang K.Y. et al. Association of hypertriglyceridemia and insulin resistant in uremic patients undergoing CAPD. Perit Dial Int 2001; 21: 282-289.
47. Chertow G.M., Burke S.K., Raggi P. for the Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in haemodialysis patients. Kidney Int 2002; 62: 245-252.
48. Chung S.H., Chu W.S., Lee H.A. et al. Peritoneal transport characteristics, comorbid diseases and survival in CAPD patients. Perit Dial Int 2000; 20: 541-547.
49. Chung S.H., Heimbürger O., Lindholm B., Stenvinkel P. Chronic inflammation in PD patients. In: Ronco C. (eds). Contributions to nephrology 2003; 140. Peritoneal dialysis today: 104-111. Karger.
50. Chung S.H., Lindholm B., Lee H.B. Influence of initial nutritional status on continuous ambulatory peritoneal dialysis patients survival. Perit Dial Int 2000; 20: 19-26.
51. Churchill D.N., Taylor D.W., Keshaviah P.R. for the Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous PD: Association with clinical outcomes. J Am Soc Nephrol 1996; 7: 198-207.
52. Churchill D.N., Thorpe K.E., Nolph K.D., Keshaviah P.R. et al. Increased peritoneal transport is associated with decreased patients and technique survival for continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 1998; 9: 1285-1292.
53. Churchill D.N., Thorpe K.E., Nolph K.D. et al. for CANUSA Peritoneal Dialysis Group. CAPD patients and technique survivals are worse with increased membrane permeability. Perit Dial Int 1996; 16 (Suppl. 2): 21.
54. Churchill D.N., Thorpe K.E., Vonesh E.F., Keshaviah P.R. for the Canada-USA (CANUSA) Peritoneal Dialysis Study Group: Lower probability of survival with continuous peritoneal dialysis in the United States compared with Canada. J Am Soc Nephrol 1997; 8: 965-971.
55. Coles G.A., Williams J.D. What is the place of peritoneal dialysis in the integrated treatment of renal failure? Kidney Int 1998; 54: 2234-2240.
56. Coles G.A., Williams J.D., Topley N. Peritoneal inflammation and long-term changes in peritoneal structure and function. In: Gokal R., Khanna R., Krediet R.T., Nolph K.D. (eds). Textbook of Peritoneal Dialysis (ed 2) 2000: 565-583. Dordrecht/Boston/London, Kluwer Academic Publishers.
57. Collins A.J., Hao W., Hong X. et al. Mortality risks of peritoneal dialysis and hemodialysis. Am J Kidney Dis 1999; 34: 1065-1074.
58. Correa-Rotter R., Cueto-Manzano A.M. The problem of the high transporters: is survival decreased? Perit Dial Int 2001; 21 (Suppl. 3): 75-79.
59. Cueto-Manzano A.M., Quintana-Piña E., Correa-Rotter R. Long-term CAPD survival and analysis of mortality risk factors: 12-years experience of a single mexican center. Perit Dial Int 2001; 21: 148-153.
60. Culleton B., Parfrey P.S. Cardiovascular risk in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1996; 16: 10-12.
61. Dadfar E., Lundahl J., Fernvik E. et al. Leukocyte CD11b and CD62L expression in response to interstitial inflammation in CAPD patients. Perit Dial Int 2004; 25: 28-36.
62. Danway A.B., Millar D.J. Glycation and advanced glycation end product formation with icodextrin and dextrose. Perit Dial Int 1997; 17: 52-58.
63. Dasgupta M.K. Silver-coated catheters in peritoneal dialysis. Perit Dial Int 1997; 17 (Suppl. 2): 142-145.
64. Dasgupta M.K., Larabie M. Biofilms in peritoneal dialysis. Perit Dial Int 2001; 21 (Suppl. 3): 213-217.
65. Davies S.J. Assessment of comorbidity in peritoneal dialysis patients. In: Ronco C. (eds). Contributions to nephrology 2003; 140. Peritoneal dialysis today: 98-103. Karger.
66. Davies S.J., Bryan J., Phillips L., Russel G.I. The predictive value of KT/V and peritoneal solute transport in CAPD patients is dependent on the type of comorbidity present. Perit Dial Int 1996; 16 (Suppl. 1): 158-162.
67. Davies S.J., Bryan J., Phillips L., Russell G.I. Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11: 498-506.
68. Davies S.J., Phillips L., Naish P.F., Russell G.I. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. Am Soc Nephrol 2001; 12: 1046-1051.
69. Davies S.J., Phillips L., Naish P.F., Russell G.I. Quantifying comorbidity in peritoneal dialysis patients and its relationship to other predictors of survival. Nephrol Dial Transplant 2002; 17: 1085-1092.
70. Davies S.J., Phillis L., Griffiths A.M. et al. What really happens to people on long-term peritoneal dialysis? Kidney Int 1998; 54: 2207-2217.
71. Davies S.J., Van Biesen W., Nicholas J., Lameire N. Integrated care. Perit Dial Int 2001; 21 (Suppl. 3): 269-274.
72. Dell’Aquila R., Rodighiero M.P., Bonello M., Ronco C. Conditions leading to catheter removal or substitution. In: Ronco C. (eds). Contributions to nephrology 2004; 142. Hemodialysis vascular access and peritoneal dialysis access: 435-446. Karger.
73. Di Paolo N., Garosi G., Petrini G., Sacchi G. Peritoneal dialysis solution biocompatibility testing in animals. Perit Dial Int 1995; 15 (Suppl. 7): 61-70.
74. Di Paolo N., Sacchi G. Atlas of peritoneal histology in normal condition and during peritoneal dialysis patients. Perit Dial Int 2000; 20 (Suppl. 3): 37-63.
75. Di Paolo N. The peritoneal mesotelium. An excretory organ. Perit Dial Int 1989; 9: 151-154.
76. Dobbie J.W. Peritoneal ultrastructure and changes with continuous peritoneal dialysis patients. Perit Dial Int 1993; 13 (Suppl. 2): 585-587.
77. Dobbie J.W., Jassani M.K. Role of imbalance of interactivity fibrin formation and removal in the pathogenesis of peritoneal lesions in CAPD. Perit Dial Int 1997; 17: 121-124.
78. Duoma C.E., Zweers M.M., de Waart D.R., van der Wardt A.B. et al. Substrate and inhibitor for nitric oxide synthase during peritoneal dialysis in rabbits. Perit Dial Int 1999; 19 (Suppl. 2): 358-364.
79. Fenton S.S.A., Shaubel D.E., Desmeules W. et al. Heamodialysis versus peritoneal dialysis: a comparison of adjisted mortality rates.
80. J Am Soc Nephrol 1997; 30: 334-342.
81. Feriani M., Catizone L., Fracasso A. Peritoneal dialysis solutions and systems. In: Gokal R., Khanna R., Krediet R.T., Nolph K.D. (eds). Textbook of Peritoneal Dialyasis (ed 2) 2000: 253-305. Dordrecht/Boston/London, Kluwer Academic Publishers.
82. Feriano M. Peritoneal transport in long-term peritoneal dialysis patients and its relation with AGEs. In: Ronco C. (eds). Contributions to nephrology 2001; 131. Advanced glycation end products in nephrology: 74-81. Karger.
83. Fernström A., Hylander B., Moritz A. et al. Increase of intra-abdominal fat in patients treated with CAPD. Perit Dial Int 1998; 18: 166-171.
84. Fliser P., Pacini G., Engelleiter R. et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 33: 1343-1347.
85. Foley R.N., Parfrey P.S. Cardiac disease in dialysis patients. In: Owen W.F., Pereira B.J.G., Sayegh M.H. Dialysis and transplantation: a companion to Brenner & Rector’s the kidney 2000: 221, 236, USA, W.B. Saunders Company.
86. Foley R.N., Parfrey P.S., Harnett J.D. et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease. Kidney Int 1996; 49: 1379-1385.
87. Fried L., Bernardini J., Johnston J.R., Piraino B. Peritonitis influence: mortality in peritoneal dialysis patients. J Am Soc Nephrol 1996; 7: 2176-2182.
88. Fried L., Bernardini J., Piraino B. Charlson comorbidity index as a predictor of outcomes in incident peritoneal dialysis patients. Am J Kidney Dis 2001; 37: 337-342.
89. Fried L., Piraino B. Peritonitis. In: Gokal R., Khanna R., Krediet R.T., Nolph K.D. (eds). Textbook of Peritoneal Dialyasis (ed 2) 2000: 545-564. Dordrecht/Boston/London, Kluwer Academic Publishers.
90. Fried L. High membrane permeability predict poorer patients survival. Perit Dial Int 1997; 17: 387-401.
91. Garibotto G., Saffioti S., Russo R. et al. Malnutrition in peritoneal dialysis patients: Causes and diagnosis. In: Ronco C. (eds). Contributions to nephrology 2003; 140. Peritoneal dialysis today: 112-121. Karger.
92. Garosi G. Different aspects of peritoneal sclerosis. In: Ronco C. (eds). Contributions to nephrology 2003; 140. Peritoneal dialysis today: 18-29. Karger.
93. Garosi G., Di Paolo N. Inflammation and gross vascular alternations are characteristic histological features of sclerosing peritonitis. In: Ronco C. (eds). Contributions to nephrology. Perit Dial Int 2003; 140: 18-29. Karger.
94. Giorban-Brennan N., Troidle L., Kliger A., Finkelstein F.O. Peritonitis and its relationship with death in a large CAPD cohort (Abstract). Perit Dial Int 1999; 19 (Suppl. 1): 31.
95. Glorieux G.L., Dhondt A.M., Jacobs P. et al. In vitro study of potential role of guanidines in leukocyte functions related to atherogenesis and infection. Kidney Int 2004; 65: 2184-2192.
96. Gokal R. Peritoneal dialysis in the 21-st century: An analysis of current problems and future developments. J Am Soc Nephrol 2002; 13: 104-116.
97. Gokal R. Taking peritoneal dialysis beyond the year 2000. Perit Dial Int 1999; 19 (Suppl. 3): 35-42.
98. Gokal R. History of peritoneal dialysis. In: Gokal R., Khanna R., Krediet R.T., Nolph K.D. (eds). Textbook of Peritoneal Dialysis (ed 2) 2000: 1-17. Dordrecht/Boston/London, Kluwer Academic Publishers.
99. Gokbel H., Yeksan M., Dogan E., Gundogan F. et al. Effect of CAPD applications on pulmonary function. Perit Dial Int 1998; 18: 344-345.
100. Gotloib L., Shostack A. Ultrastructural morphology of the peritoneum: New findings and speculations on transfer of solutes and water during peritoneal dialysis. Perit Dial Bull 1987; 7: 119-129.
101. Gotloib L., Shostack A., Walsbrot V. Functional structure of the peritoneum as a dialysis membrane. In: Gokal R., Khanna R., Krediet R.T., Nolph K.D. (eds). Textbook of Peritoneal Dialysis (ed 2) 2000: 37-106. Dordrecht/Boston/London, Kluwer Academic Publishers.
102. Gotloib L., Wajsbrot V., Shostack A. Ecology of the peritoneum: A substantial role for the osmotic agents resulting in apoptosis of mesothelial cells. In: Ronco C. (eds). Contributions to nephrology 2003; 140. Peritoneal dialysis today: 10-17. Karger.
103. Griffith T.F., Reddan D.N., Klassen P.S., Owen W.F. Left ventricular hypertrophy: a surrogate end point or correlate of cardiovascular events in kidney disease? Nephrol Dial Transplant 2003; 18: 2482-2485.
104. Guidelines for adequacy and nutrition in peritoneal dialysis. In: Clinical Practice Guidelines of the Canadian Society of Nephrology for Treatment of Patients with Chronic Renal Failure. J Am Soc Nephrol 1999; 10 (Suppl. 13): 287-321.
105. Guo A., Mujais S. Patient and technique survival on peritoneal dialysis in the United States: evaluation in large incident cohorts. Kidney Int 2003; 64 (Suppl. 88): 3-12.
106. Ha H., Lee H.B. Effect of high glucose on peritoneal mesothelial cell biology. Perit Dial Int 2000; 20 (Suppl. 2): 15-18.
107. Harnett J.D., Foley R.N., Parfrey P.S. Left ventricular dysfunction in dialysis subjects. In: Henrich W.L. (ed). Principles and practice of dialysis (ed. 2) 1999: 235-245, Hong Kong Williams & Wilkins.
108. Harris S.A.C., Lamping D.L., Brown E.A., Constantinovici N. for the North Thames Dialisis Study (NTDS) Group. Clinical outcomes and quality of life in elderly patients on peritoneal dialysis versus hemodialysis. Perit Dial Int 2002; 22: 463-470.
109. Harwell C.M., Newman L.N., Cacho C.P., Schulak J.A. et al. Abdominal catastrophe: visceral injury as a cause of peritonitis in patients treated by peritoneal dialysis. Perit Dial Int 1997; 17: 586-594.
110. Hausmann M.J., Vorobiov M., Ovnat A. Small bowel obstruction due to localized Tenckhoff catheter-related adhesions. Perit Dial Int 2002; 22: 431-432.
111. Heaf J. High transport and malnutrition-inflammation-atherosclerosis (MIA) syndrome. Perit Dial Int 2003; 23: 109-110.
112. Heimbürger O., Wang T., Lindholm B. Alterations in water and solute transport with time on peritoneal dialysis. Perit Dial Int 1999; 19 (Suppl. 2): 83-90.
113. Hendriks P.M.E.M., Ho-dac-Pannekeet M.M., van Gulik T.M. et al. Peritoneal sclerosis in chronic peritoneal dialysis patients: Analysis of clinical presentation, risk factors, and peritoneal transport kinetics. Perit Dial Int 1997; 17: 136-143.
114. Himmelfarb J., Stenvinkel P., Ilkizler T.A., Hakim R.M. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538.
115. Ho-dac Pannekeet M.M., Weiss M.F., de Waart D.R., Erhard P. et al. Analysys of non enzymatic glycosylation in vivo: impact of different dialysis solutions. Perit Dial Int 1999; 19 (Suppl. 2): 69-74.
116. Hoeben H., Van Biesen W., Lameire N. Cardiovascular problems in peritoneal dialysis patients: short overview. Perit Dial Int 1999; 19 (Suppl. 2): 150-158.
117. Iliescu E.A., Marcovina S.M., Morton A.R. et al. Apolipoprotein(a) phenotype and lipoprotein(a) level predict peritoneal dialysis patient mortality. Perit Dial Int 2002; 22: 492-499.
118. Inagi R., Miyata T. Oxidative protein damage with carbonhydrates and lipids in uremia: «carbonyl stress». Haemodialysis and oxidant stress. Lameire N., Tetta C., Ronco C. (eds) 1999: 41-52. Karger.
119. Jörres A. PD: a biological membrane and a non-biological fluid. In: Ronco C. (eds). Contributions to nephrology 2003; 140. Peritoneal dialysis today: 1-9. Karger.
120. Kang D.H., Hong Y.S., Lim H.J. et al. High glucose solution and spent dialysate stimulate of transforming growth factor-β1 of human peritoneal mesothelial cells: Effect of cytokine co-stimulation. Perit Dial Int 1999; 19: 221-230.
121. Kawaguchi Y. National comparisons: optimal peritoneal dialysis outcomes among japanese patients. Perit Dial Int 1999; 19 (Suppl. 3): 9-16.
122. Kawaguchi Y. Peritoneal dialysis as a long-term treatment: comparison of technique survival between asian and western populations. Perit Dial Int 1999; 19 (Suppl. 2): 327-331.
123. Kawaguchi Y. Socioeconomic aspects of peritoneal dialysis: Role of non medical factors in chronic dialysis - dialysis in Asia, regional differences. Perit Dial Int 1999; 19 (Suppl. 2): 423-426.
124. Kawaguchi Y., Hasegawa T., Nakayama M. et al. Issues affecting longevity of continuous peritoneal dialysis therapy. Kidney Int 1997; 52 (Suppl. 62): 105-107.
125. Kawaguchi Y., Kawanishi H., Mujais S. et al. Encapsulating peritoneal sclerosis: Definition, etiology, diagnosis and treatment. Perit Dial Int 2000; 20 (Suppl. 4): 43-55.
126. Kawanishi H. Encapsulating peritoneal sclerosis in Japan: prospective multicenter controlled study. Perit Dial Int 2001; 21 (Suppl. 3): 67-71.
127. Khanna R., Nolph K.D., Oreopoulos D.G. Techniques, prescriptions and indications. The essentials of peritoneal dialysis 1993: 35-44. Dordrecht/Boston/London, Kluwer Academic Publishers.
128. Kim D.J., Kang W.-H., Kim H.Y. et al. The effect of dialysate dwell on gastric emptying time in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1999; 19 (Suppl. 2): 170-183.
129. Kim K.J., Yang W.S., Kim S.B. et al. Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin. Perit Dial Int 1997; 17: 157-161.
130. Kim M., Lofthouse J., Flessner M.F. Blood flow limitations of solute transport across the visceral peritoneum. J Am Soc Nephrol 1997; 8: 1946-1950.
131. Kim S.B., Yang W.S., Chi H.S., Park J.S. Effect of increasing serum albumin on plasma D-dimer and von Willebrand factor levels and platelet aggregation in CAPD patients. Am J Kidney Dis 1999; 33: 312-317.
132. Kim S.B., Yang W.S., Park J.S. Role of hypoalbuminemia in the genesis of cardiovascular disease in dialysis patients. Perit Dial Int 1999; 19 (Suppl. 2): 144-149.
133. Klefter R., Lokkegaard H. Risk factors in CAPD patients. Perit Dial Int 1997; 17: 98.
134. Koch M., Kutkuhn B., Trenkwalder E. et al. Apolipoprotein B, fibrinogen, HDL, cholesterol, and apolipoprotein (a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 1997; 8: 1889-1898.
135. Konings C.J.A.M., Kooman J.P., Schonck M. et al. Fluid status, blood pressure, and cardiovascular abnormalities in patients on peritoneal dialysis. Perit Dial Int 2002; 22: 477-487.
136. Korevaar J.C., van Manen J.G., Dekker F.W. et al. for the NECOSAD Study Group. Evalution of guidelines for peritoneal dialysis patients: a review from the Netherlands Cooperative Study on the adequacy of dialysis (NECOSAD). In: Ronco C. (eds). Contributions to nephrology 2003; 140. Peritoneal dialysis today: 142-150. Karger.
137. Krediet R.T. Biological markers in peritoneal effluent: Are they useful? In: Ronco C. (eds). Contributions to nephrology 2003; 140. Peritoneal dialysis today: 30-37. Karger.
138. Krediet R.T. Dialysate cancer antigen 125 concentration as marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 2001; 21: 560-567.
139. Krediet R.T. Peritoneal anatomy and physiology during peritoneal dialysis. In: Jacobs C., Kjellstrand C.M., Koch K.M., Winchester J.F. (eds). Replacement of Renal Function by Dialysis (ed 4) 1996, Dordrecht/Boston/London, Kluwer Academic Publishers.
140. Krediet R.T. The peritoneal membrane in chronic peritoneal dialysis. Kidney Int 1999; 55: 341-356.
141. Krediet R.T., Zweers M.M., Van der Wal A.C., Struijk D.G. Neoangiogenesis in the peritoneal membrane. Perit Dial Int 2000; 20 (Suppl. 2): 19-25.
142. Kumano K., Shimoda M., Hyodo T. The role of TGFβ growth inhibition of peritoneal mesothelial cells in high-glucose dialysate. Perit Dial Int 1995; 15 (Suppl. 7): 93-95.
143. Lai K.N., Lam M.F., Leung J.C. Peritoneal function: the role of aquaporins. Perit Dial Int 2003; 23 (Suppl. 2): 20-25.
144. Lai K.N., Li F.K., Lan H.Y. et al. Expression of aquaporin-1 in human peritoneal mesothelial cells and its upregulation by glucose in vitro. J Am Soc Nephrol 2001; 12: 1036-1045.
145. Lameire N., Biesen W.V., Vanholder R. Impact of peritoneal dialysis on patient and graft outcomes after kidney transplantation. In: Ronco C. (eds). Contributions to nephrology 2003; 140. Peritoneal dialysis today: 226-241. Karger.
146. Lameire N., Van Biesen W. Long-term peritoneal dialysis: does a spell of peritoneal dialysis prolong survival on hemodialysis. In: Brown E.A. and Parfrey P.S. (eds). Complications of long-term dialysis 1999: 276-299. Oxford University Press.
147. Lameire N., Van Biesen W. The impact of residual renal function on the adequacy of peritoneal dialysis. Perit Dial Int 1997; 17 (Suppl. 2): 103-110.
148. Lameire N., Van Biesen W., Vanholder R. The role of peritoneal dialysis as first modality in an integrative approach to patients with end-stage renal disease. Perit Dial Int 2000; 20 (Suppl. 2): 134-141.
149. Lameire N.H., Mortier S., De Vriese A. Peritoneal microcirculation. In: Ronco C. (eds). Contributions to nephrology 2003; 140. Peritoneal dialysis today: 56-69. Karger.
150. Lameire N.H., Vanholder R., Veyt D. et al. Longitudinal, five year survey of urea kinetic parameters in CAPD patients. Kidney Int 1992; 42: 426-432.
151. Lapolla A., Traldi P., Fedele D. AGE in micro- and macroangiopathy. In: Ronco C. (eds). Contributions to nephrology 2001; 131. Advanced glycation end products in hephrology: 10-21. Karger.
152. Leblanc M., Ouimet D., Tremblay C., Nolin L. Peritoneal instillation test before CAPD in a case of severe pulmonary disease. Perit Dial Int 1995; 15: 384-387.
153. Ledebo I., Wieslander A., Deppisch R. GDPs and AGEs: local and systemic effects in PD patients. In: Ronco C. (eds). Contributions to nephrology 2003; 140. Peritoneal dialysis today: 38-46. Karger.
154. Leehey D.J., Daugirdas J.T. Complications other than peritonitis. In: Daugirdas J.T., Ing T.S. (eds). Handbook of Dialyasis (ed 2) 1994: 363-366. Boston/Little/Brown.
155. Leehey D.J., Gandhi V.C., Daugirdas J.T. Peritonitis and exit-site infection. In: Daugirdas J.T., Ing T.S. (eds). Handbook of Dialysis (ed 2) 1994: 338-362. Boston/Little/Brown.
156. Levine S., Saltzman A. Abdominal cocon: an animal model for a complication of peritoneal dialysis. Perit Dial Int 1996; 16: 613-616.
157. Li F.K. Effect of peritoneal dialysis on peritoneal macrophages. Perit Dial Int 1999; 19 (Suppl. 2): 343-347.
158. Liu H.-L., Husng J.-J., Lan R.-R. et al. Ishaemic bowel disease in patients on continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1999; 14: 2032-2034.
159. Lo W.-K., Lui S.-L., Li F.-K., Cheng I.K.P. Fungal peritonitis-current status 1998. Perit Dial Int 1999; 19 (Suppl. 2): 286-290.
160. Lo W.-K., Tong K.-L., Li C.-S. et al. Relationship between adequacy of dialysis and nutritional status, and their impact on patient survival on CAPD in Hong Kong. Perit Dial Int 2001; 21: 441-447.
161. Locatelli F., Canaud B., Eckardt K.U. et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18 (Suppl. 7): 1272-1280.
162. Longenecker J.C., Corech J., Klag M.J. et al. for the CHOICE Study. Validation of comorbid conditions on the End-Stage Renal Disease Medical Evidence Report: the Choice Study. J Am Soc Nephrol 2000; 11: 520-529.
163. Maitra S., Burkart J., Fine A. et al. Patients on chronic peritoneal dialysis for ten years or more in North America. Perit Dial Int 2000; 20 (Suppl. 2): 127-133.
164. Majewska E., Baj Z., Sulowska Z. et al. Effects of uremia and hemodialysis on neutrophil apoptosis and expression of apoptosis-related proteins. Nephrol Dial Transplant 2003; 18: 2582-2588.
165. Margetts P.J., McMullin J.P., Rabbat C.G., Churchill D.N. Peritoneal membrane transport and hypoalbuminemia: Cause or effect? Perit Dial Int 2000; 20: 14-18.
166. Mateijsen M.A.M., van der Wal A.C., Hendriks P.M.E.M. et al. Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 1999; 19: 517-525.
167. McLaughlin K., Butt G., Madi A. et al. Sclerosing peritonitis occuring in hemodialysis patient. Am J Kidney Dis 1996; 27: 729-732.
168. Mehrotra R., Nolph K.D. Current status of peritoneal dialysis. In: Gokal R., Khanna R., Krediet R.T., Nolph K.D. (eds). Textbook of Peritoneal Dialysis (ed 2) 2000: 19-35. Dordrecht/Boston/London, Kluwer Academic Publishers.
169. Menkus M.P., Jager K.J., Dekker F.W. for the NECOSAD Study Group. Predictors of poor outcome in chronic dialysis patients: the Netherlands Cooperative Study on the adequacy of dialysis. Am J Kidney Dis 2000; 35: 69-79.
170. Misra M., Khanna R. Peritoneal dialysis in diabetic end-stage renal disease. In: Gokal R., Khanna R., Krediet R.T., Nolph K.D. (eds). Textbook of Peritoneal Dialyasis (ed 2) 2000: 647-665. Dordrecht/Boston/London, Kluwer Academic Publishers.
171. Miyata T., Izuhara Y., Sakai H., Kurokawa K. Carbonyl stress: increased carbonyl modification of tissue and cellular proteins in uremia. Perit Dial Int 1999; 19 (Suppl. 2): 58-61.
172. Mujais S. Ultrafiltration failure. In: Gokal R., Khanna R., Krediet R.T., Nolph K.D. (eds). Textbook of Peritoneal Dialyasis (ed 2) 2000: 499-513. Dordrecht/Boston/London, Kluwer Academic Publishers.
173. Musi B., Braide M., Carlsson O., de Haan R.J., Boeschoten E.W., Krediet R.T. Biocompatibility of peritoneal dialysis fluids: Long-term exposure of nonuremic rats. Perit Dial Int 2004; 24: 37-47.
174. Nagai T., Kutiyama M., Kawada Y. Oxidative metabolism of polymorphonuclear leukocytes in continuous ambulatory peritoneal dialysis. Perit Dial Int 1997; 17: 167-174.
175. Nagy J.A., Jackman R.W. Peritoneal membrane biology. In: Owen W.F., Pereira B.J.G., Sayegh M.H. Dialysis and transplantation: a companion to Brenner & Rector’s the kidney 2000: 109-128, USA, W.B. Saunders Company.
176. National Kidney Foundation. K/DOQI clinical practice guidelines for peritoneal dialysis adequacy, 2000. Am J Kidney Dis 2001; 37 (Suppl. 1): 65-136.
177. Nicholls A.J. Heart and circulation. In: Daugirdas J.T., Ing T.S. (eds). Handbook of Dialysis (ed 2) 1994: 604-622. Boston/Little/Brown.
178. Nolph K.D. Continuous ambulatory peritoneal dialysis. Am J Nephrol 1981; 1: 1-10.
179. Numata M., Nakayama M., Nimura S., de Haan R.J., Boeschoten E.W., Krediet R.T. Association between an increased surface area of peritoneal microvessels and a high peritoneal solute transport rate. Perit Dial Int 2003; 23: 116-122.
180. Ortiz A., Catalán M.P. Will modulation of cell death increase PD technique survival? Perit Dial Int 2004; 24: 105-114.
181. Paganini E.P. Hematologic abnormalities. In: Daugirdas J.T., Ing T.S. (eds). Handbook of Dialysis (ed 2) 1994: 445-468. Boston/ Little/Brown.
182. Paniagua R., Amato D., Vonesh E., de Haan R.J., Boeschoten E.W., Krediet R.T. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomised, controlled trial. J Am Soc Nephrol 2002; 13: 1307-1320.
183. Panichi V., Migliori M., De Pietro S., de Haan R.J., Boeschoten E.W., Krediet R.T. et al. C-reactive protein as a marker of chronic inflammation in uremic patients. In: Botella J., Klinkmann H., La Greca G., Zucchelli P. (eds). Chronic inflammation in hemodialysis 2000: 17-24. Karger.
184. Pannekeet M.M., Zemel D., Koomen G.C.M. et al. Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD. Perit Dial Int 1995; 15: 217-225.
185. Park M.S., Lee H.B. AGE accumulation in peritoneal membrane and cavity during peritoneal dialysis and its effect on peritoneal structure and function. Perit Dial Int 1999; 19 (Suppl. 2): 58-61.
186. Park M.S., Lee H.B., Chu W.S. et al. Peritoneal accumulation of AGE and peritoneal membrane permeability. Perit Dial Int 2000; 20 (Suppl. 4): 452-460.
187. Passadakis P., Thodis E., Vargemezis V., Oreopoulos D.G. Nutrition in diabetic patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 1999; 19 (Suppl. 2): 248-254.
188. Passlick-Deetjen J., Piscetsrieder M., Witowski J. et al. In vitro superiority of dual-chamber peritoneal dialysis solutions with possible clinical benefits. Perit Dial Int 2001; 21 (Suppl. 3): 96-101.
189. Pawlaczyk K., Kuzlan-Pawlaczyk M., Wieczorowska-Tobis K. et al. Bicarbonate/lactate dialysis solution improves in vivo function of peritoneal host defense in rats. Perit Dial Int 1999; 19 (Suppl. 2): 370-377.
190. Pawlaczyk K., Kuzlan-Pawlaczyk M., Wieczorowska-Tobis K. et al. Effect of N-acetylglucosamine on function of peritoneal leukocytes. Perit Dial Int 1999; 19 (Suppl. 2): 365-369.
191. Pecoits-Filho R., Barany P., Lindholm B. et al. Interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol Dial Transplant 2002; 17: 1684-1688.
192. Pecoits-Filho R., Stenvinkel P., Wang A.Y.-M. et al. Chronic inflammation in peritoneal dialysis patients: The search for the Holy Grail? Perit Dial Int 2004; 24: 327-339.
193. Pollock C. Diagnosis and management of encapsulating peritoneal sclerosis. Perit Dial Int 2001; 21 (Suppl. 3): 61-66.
194. Pollock C.A., Cooper B.A., Ibels L.S., de Kantzow E. Nutritional aspects of peritoneal dialysis. In: Gokal R., Khanna R., Krediet R.T., Nolph K.D. (eds). Textbook of Peritoneal Dialyasis (ed 2) 2000: 515-544. Dordrecht/Boston/London, Kluwer Academic Publishers.
195. Popovich R.P., Moncrief J.W., Decherd J.F. et al. The definition of novel portable/wearable equilibrium dialysis technique (Abstract). Trans Am Soc Artif Intern Organs 1976; 5: 64.
196. Popovich R.P., Moncrief J.W., Nolph K.D. et al. Continuous ambulatory peritoneal dialysis technique. Ann Intern Med 1978; 88: 449-456.
197. Prichard S. Cardiovascular risk in peritoneal dialysis. In: Ronco C. (eds). Contributions to nephrology 2003; 140. Peritoneal dialysis today: 82-90. Karger.
198. Prichard S. Major and minor risk factors for cardiovascular disease in problems in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1999; 19 (Suppl. 2): 133-137.
199. Prichard S., Cianflone K., Sniderman A. The role of the liver in pathogenesis of hyperlipidemia in patients with end-stage renal disease treated with continuous ambulatory peritoneal dialysis. Perit Dial Int 1996; 16 (Suppl. 1): 207-210.
200. Prichard S., Sniderman A., Cianflone K., Marpole D. Cardiovascular disease in peritoneal dialysis. Perit Dial Int 1996; 16: 19-22.
201. Ramon R.C., Carrasco A.M. Hydrothorax in peritoneal dialysis. Perit Dial Int 1998; 18: 5-10.
202. Rashid G., Luzon A.-A., Korzets Z. et al. The effect of advanced glycation end-products and aminoguanidine on TNFα production by rat peritoneal macrophages. Perit Dial Int 2001; 21: 122-129.
203. Ritzau J., Hoffman R.M., Tzamaloukas A.H. Effect of preventing Staphylococcus aureus carriage on rates of peritoneal catheter-related staphylococcal infections. Literature synthesis. Perit Dial Int 2001; 21: 471-479.
204. Rocco M.V., Frankenfield D.L., Frederick P. et al. for the National ESRD Core Indicators Workgroup. Intermediate outcomes by race and ethnicity in peritoneal dialysis patients: results from the 1997 Core Indicators project. Perit Dial Int 2000; 20: 328-335.
205. Rocco M.V., Frankenfield D.L., Prowant B. et al. Risk factors for mortality in U.S. peritoneal dialysis patients: impact of residual renal function. Perit Dial Int 2002; 22: 371-379.
206. Rodrigues A., Verger C. Peritoneal access. In: Ronco C. (eds). Contributions to nephrology 2003; 140. Peritoneal dialysis today: 195-201. Karger.
207. Rossert J.A., Wauters J.-P. Recommendations for the screening and management of patients with chronic kidney disease. Nephrol Dial Transplant 2002; 17 (Suppl. 1): 19-28.
208. Rugiu C., Lupo A., Bernich P. et al. 14-year experience with Double-Cuff straight Tenckhoff catheter. Perit Dial Int 1997; 17: 301-303.
209. Sanusi A.A., Zweers M.M., Weening J.J. et al. Expression of cancer antigen 125 peritoneal mesothelial cells is not influenced by duration of peritoneal dialysis. Perit Dial Int 2001; 21: 495-500.
210. Schaubel D.E., Blake P.G., Fenton S.S.A. Trends in CAPD technique failure: Canada, 1981-1997. Perit Dial Int 2001; 21: 365-371.
211. Schaubel D.F., Fenton S.S.A. Trends in mortality on peritoneal dialysis: Canada 1981, 1997. J Am Soc Nephrol 2000; 11: 126-133.
212. Schleicher E.D., Bierhaus A., Häring H.-U. et al. Chemistry and pathobiology of advanced glycation end products. In: Ronco C. (eds). Contributions to nephrology 2001; 131. Advanced glycation end products in nephrology: 1-9. Karger.
213. Shetty H., Gokal R. Peritoneal dialysis as a first-choice treatment. In: Ronco C. (eds). Contributions to nephrology 2003; 140. Peritoneal dialysis today: 218-225. Karger.
214. Shetty H., Gokal R. Treatment of infections in peritoneal dialysis. In: Ronco C. (eds). Contributions to nephrology 2003; 140. Peritoneal dialysis today: 187-194. Karger.
215. Siamopoulus K.C., Elisaf M. Is CAPD atherogenic? Perit Dial Int 1997; 17: 227-231.
216. Silang R., Regalado M., Cheng T.H., Wesson D.E. Prokinetic agents increase plasma albumin in hypoalbuminemic chronic dialysis patients with delayed gastric emptying. Am J Kidney Dis 2001; 37: 287-293.
217. Stenvinkel P., Chung S.H., Heimbürger O., Lindholm B. Malnutrition, inflammation and atherosclerosis in peritoneal dialysis patients. Perit Dial Int 2001; 21 (Suppl. 3): 157-162.
218. Stenvinkel P., Heimbürger O., Tuck C.H., Berglund L. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int 1998; 53: 1336-1342.
219. Struijk D.G., Krediet R.T., Koomen G.C., Hoek F.J. et al. Functional characteristics of the peritoneal membrane in long-term continuous ambulatory peritoneal dialysis. Nephron 1991; 59: 213-220.
220. Struijk D.G., Krediet R.T., Koomen G.C.M. et al. A prospective study of peritoneal transport in CAPD patients. Kidney Int 1994; 45: 1739-1744.
221. Szeto C.C., Chow K.M., Leung C.B. et al. Clinical course of peritonitis due to Pseudomonas species complicating peritoneal dialysis: A review of 104 cases. Kidney Int 2001; 59: 2309-2315.
222. Szeto C.C., Law M.-C., Wong T.Y.-H. et al. Peritoneal transport status correlates with morbidity but not longitudinal change of nutritional status of continuous ambulatory peritoneal dialysis patients: A 2-year prospective study. Am J Kidney Dis 2001; 37: 337-342.
223. Tanna M.M., Vonesh E.F., Korbet S.M. Patient survival among incident peritoneal dialysis and hemodialysis patients in an urban setting. Am J Kidney Dis 2000; 36: 1175-1182.
224. Thodis E., Passadakis P., Vargemezis V., Oreopoulos D.G. Peritoneal dialysis: better than, equal to, or worse than hemodialysis? Data worth knowing before choosing a dialysis modality. Perit Dial Int 2001; 21: 25-35.
225. Twardowski Z.J., Nichols W.K. Peritoneal dialysis access and exit-site care including surgical aspects. In: Gokal R., Khanna R., Krediet R.T., Nolph K.D. (eds). Textbook of Peritoneal Dialyasis (ed 2) 2000: 307-361. Dordrecht/Boston/London, Kluwer Academic Publishers.
226. Twardowski Z.J., Nolph K.D., Khanna R. et al. Peritoneal equilibration test. Perit Dial Bull 1987; 6: 131-137.
227. US Renal Data System: USRDS 2001, Annual Data Report. Bethesda, MD, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, 2001.
228. US Renal Data System: USRDS 2001, Annual Data Report. Bethesda, MD, National Institutes of Health, National Institutes of Diabetes and Digestive and Kidney Diseases, 2003.
229. Usha K., Ponferrada L., Prowant B.F., Twardowski Z.J. Repair of chronic peritoneal dialysis catheter. Perit Dial Int 1998; 22: 419-423.
230. Van Biesen W., Vanholder R., Lameire N. The role of peritoneal dialysis as the first-line renal replacement modality. Perit Dial Int 2000; 20: 375-383.
231. Van Biesen W., Wiedemann M., Lameire N. End-stage renal disease treatment: a European perspective. J Am Soc Nephrol 1999; 9: 1-8.
232. Van Manen J.C., Korevar J.C., Dekker F.W. et al. How to adjust for comorbidity in survival studies in ESRD patients: a comparison of different indices. Am J Kidney Dis 2002; 40: 82-98.
233. Van Olden R.W., Krediet R.T., Struijk D.G., Arisz L. Measurement of residual renal function in patients treated with continuous peritoneal dialysis. J Am Soc Nephrol 1996; 7: 745-748.
234. Vanholder R., De Smet R., Jacobs V. et al. Uremic toxic retention solutes depress polymorphonuclear response to phagocytosis. Nephrol Dial Transplant 1994; 9: 1271-1278.
235. Vanholder R., Van Loo A., Dhondt A.M. et al. Influence of uremia and hemodialysis on host defence and infection. Nephrol Dial Transplant 1996; 11: 593-598.
236. Venkataraman V., Nolph K.D. Socioeconomic aspects of peritoneal dialysis in North America: Role of non medical factors in the choice of dialysis. Perit Dial Int 1999; 19 (Suppl. 2): 419-422.
237. Verger C. Maintenance of functioning PD access and management of complications. In: Ronco C. (eds). Contributions to nephrology, 2004; 142. Hemodialysis vascular access and peritoneal dialysis access: 410-421. Karger.
238. Wai-Kei L. What factors contribute to differences in the practice of peritoneal dialysis between asian countries and the west? Perit Dial Int 2002; 22: 249-257.
239. Wang A.Y., Wang M., Woo J. et al. A novel association between residual renal function and left ventricular hypertrophy in peritoneal dialysis patients. Kidney Int 2002; 62: 639-647.
240. Wang M.-C., Tseng C.-C., Tsai W.-C., Huang J.-J. Blood pressure and left ventricular hypertrophy in peritoneal dialysis patients on different peritoneal dialysis regimens. Perit Dial Int 2001; 21: 36-42.
241. Wang T., Heimbürger O., Cheng H.-H. et al. Does a high peritoneal transport rate reflect a state of chronic inflammation? Perit Dial Int 1999; 19: 17-22.
242. Wang T., Lindholm B. Peritoneal dialysis solutions. Perit Dial Int 2001; 21 (Suppl. 3): 89-95.
243. White R., Granger D.N. Peritoneal microcirculation in peritoneal dialysis. In: Gokal R., Khanna R., Krediet R.T., Nolph K.D. (eds). Textbook of Peritoneal Dialyasis (ed 2) 2000: 107-133. Dordrecht/Boston/London, Kluwer Academic Publishers.
244. Wieczorowska-Tobis K., Brelinska R., Witowski J. et al. Evidence for less irritation to the peritoneal membrane in rats dialyzed with solutions low in glucose degradation products. Perit Dial Int 2004; 24: 48-57.
245. Williams J.D., Craig K.J., Topley N. et al. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470-479.
246. Witowski J., Jörres A. Glucose degradation products: relationship with cell damage. Perit Dial Int 2000; 20 (Suppl. 2): 31-36.
247. Witowski J., Topley N., Jörres A. et al. Effect of lactate-buffered peritoneal dialysis fluids on human peritoneal mesothelial cells and interleukin-6 and prostaglandin synthesis. Kidney Int 1995; 47: 282-293.
248. Witowski J., Wisniewska J., Kotybalska K. et al. Prolonged exposure to glucose degradation products impairs viability and function of human peritoneal mesothelial cells. J Am Soc Nephrol 2001; 12: 2434-2441.
249. Wolfe R.A., Hirth R.A., Port F.K. Mortality and costs in the first year of dialysis: comparison between hemodialysis and peritoneal dialysis controlling costs prior to ESRD. J Am Soc Nephrol 1998; 9: 241A.
250. Yang W.S., Kim S.B., Min W.K., Park J.S. Effect of increasing serum albumin on serum lipoptotein(a) concentration in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1997; 30: 507-13.
251. Yu C.-C., Wu M.-S., Yang C.-W. et al. Predialysis glycemic control is an independent predictor of clinical outcome in type II diabetics on continuous ambulatory peritoneal dialysis. Perit Dial Int 1997; 17: 262-268.
252. Zareie M., Hekking L.H.P., Welten A.G. et al. Contribution of lactate buffer, glucose and glucose degradation products to peritoneal injury in vivo. Nephrol Dial Transplant 2003; 18: 2629-2637.
253. Zheng Z., Ye R., Yu X. et al. Peritoneal dialysis solutions disturb the balance of apoptosis and proliferation of peritoneal cells in chronic dialysis model. Adv Perit Dial 2001; 17: 53-57.
254. Zimmerman J., Herrlinger S., Pruy A. et al. Inflammation enhances cardiovascular risk and mortality in haemodialysis patients. Kidney Int 1999; 55: 648-658.
255. Zoccali C., Benedetto F.A., Maas R. et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13: 490-496.

Другие статьи по теме

• Сроки начала и другие факторы на старте диализа, влияющие на выживаемость: Санкт-Петербургский регистр пациентов на заместительной почечной терапии
• Фармакоэкономическая оценка оказания медицинской помощи пациентам с терминальной почечной недостаточностью, нуждающимся в проведении диализа
• Первый опыт работы областного нефрологического центра
• Витамин Д дефицитные состояния и нарушения фосфорно-кальциевого обмена у детей на диализе и после трансплантации почки: диагностика и лечение